Nvidia stock rises on China H200 order report before the open — what to watch for NVDA next

Nvidia stock rises on China H200 order report before the open — what to watch for NVDA next

New York, Jan 23, 2026, 08:54 (EST) — Premarket

  • Nvidia shares nudged up in premarket trading following a report linking potential China orders to its H200 AI chips.
  • The stock ended Thursday at $184.84, pushing its rally into a second day.
  • Attention turns to next week’s Fed decision and a busy schedule of big-tech earnings, with Nvidia set to report on Feb. 25.

Nvidia shares climbed about 1.3% in premarket trading Friday following reports that Chinese regulators have told Alibaba, Tencent, and ByteDance they can start placing orders for Nvidia’s H200 AI chips. The gains came ahead of the U.S. market open. (Reuters)

The China signal is crucial since investors view the country as a key market for Nvidia’s data-center sales, despite the uncertain pipeline caused by U.S. export controls and Chinese approvals. Even a slight change in policy outlook can send the stock moving fast.

The H200, a data-center chip designed for training and running AI models, has become a flashpoint. Traders see the China-related stop-start as tied to both demand and politics—and the lines between the two keep blurring.

Nvidia ended Thursday’s session at $184.84, marking a 0.83% rise. The day before, shares had climbed 2.95%. (StockAnalysis)

The report offered few details, and “prepare orders” falls short of full approval. Investors want to see what comes next: concrete rules, official paperwork, clear timelines—anything that moves a headline closer to actual shipments.

Investors face a packed schedule of megacap earnings this week, still searching for signs that AI investments are translating into profit growth. “Earnings are the driver,” said Chris Galipeau, senior market strategist at Franklin Templeton. Yung-Yu Ma, chief investment strategist at PNC Financial Services Group, described the market’s recent moves as “a little bit of a short but steep roller-coaster ride.” (Reuters)

The Federal Reserve’s upcoming two-day policy meeting is set for Jan. 27–28. The rate decision and Chair Jerome Powell’s press conference will come Wednesday afternoon. Growth stocks sensitive to rates, like Nvidia, could react sharply depending on the Fed’s stance on cuts. (Federal Reserve)

Nvidia is set to announce its fourth-quarter results on Feb. 25, per the company’s investor calendar. Investors will be focused on updates about data-center demand, supply chain issues, and any clear insights on the China market. (Nvidia)

China trade continues to pose a headline risk. Delays in approval, changing purchase terms, or fresh twists in U.S.-China policy might spark renewed volatility, particularly since the stock still prices in expectations alongside actual deliveries.

Friday’s session will test if Nvidia can maintain its early gains amid chipmakers’ reactions to Intel’s earnings and the market’s focus on the Jan. 28 Fed decision. The next major event for NVDA is its earnings report on Feb. 25.

Stock Market Today

  • Hitachi (TSE:6501) Valuation Reviewed Amid Strong Share Price Gains
    January 23, 2026, 9:29 AM EST. Hitachi's share price has shown notable momentum, rising 6.24% over the past 30 days and nearly 16% over 90 days, with a one-year shareholder return of 32.91%. Currently priced at ¥5,299, Hitachi sits slightly below its fair value estimate of ¥5,600.96, suggesting modest upside potential. Expansion into digital services and acquisitions like GlobalLogic bolster profit margins and long-term growth prospects. However, risks persist, including rising project costs and weakening demand in key sectors such as China's elevator market. Valuation metrics reveal a price-to-earnings (P/E) ratio of 30.1x, well above the Asian Industrials average of 11.9x, signaling premium market expectations. Investors should weigh strong growth drivers against elevated valuation and sector-specific challenges when considering Hitachi stock.
Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path
Previous Story

Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path

Go toTop